Evidence map›Paper›PMID 41587074›Full record

ArticleBlood2026

Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation.

Kristina Roth, Dennis Loeffler, Conny Blumert, Alexander Scholz, Kristin Reiche, Marcus Bauer, Claudia Wickenhauser, Denise Schiefer, Nadja Hilger, André-René Blaudszun and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Kristina RothDepartment of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.ORCID 0009-0003-6863-5803
Dennis LoefflerDepartment of Medical Bioinformatics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.ORCID 0009-0003-8493-2189
Conny BlumertDepartment of Medical Bioinformatics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Alexander ScholzDepartment of Medical Bioinformatics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.ORCID 0009-0002-1072-3061
Kristin ReicheDepartment of Medical Bioinformatics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.ORCID 0000-0002-4452-4872
Marcus BauerInstitute of Pathology, University Medicine Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Claudia WickenhauserInstitute of Pathology, University Medicine Halle, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.ORCID 0000-0002-1807-5575
Denise SchieferDepartment of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Nadja HilgerDepartment of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
André-René BlaudszunDepartment of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.ORCID 0000-0002-0208-6894
Jenifer TheesDepartment of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Jasmin WalterDepartment of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
U Sandy TretbarDepartment of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Ulrike KoehlDepartment of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.ORCID 0000-0002-8159-9160
Stephan FrickeDepartment of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Ulrich BlacheDepartment of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.ORCID 0000-0003-4233-2268

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractGraft-versus-host disease (GVHD) remains one of the major complications following allogeneic hematopoietic cell transplantation. Currently, immunosuppressants are used for GVHD prophylaxis and treatment in most transplantation recipients. Due to their systemic, nonspecific mode of action, this treatment regimen is frequently associated with severe toxic side effects, opportunistic infections, as well as cancer relapse when treating hematologic malignancies. By using short-term ex vivo modulation of hematopoietic cell transplants with the anti-human CD4 antibody MAX.16H5, we have developed a novel immune tolerance-inducing strategy enabling potent GVHD prevention. Functional in vitro assays and transcriptome profiling data suggest impaired T-cell receptor signaling and a shift toward an interleukin-10-dependent regulatory phenotype as the primary mechanism of action of anti-human CD4 antibody treatment, leading to significantly reduced activation and proliferation of CD4+ and CD8+ T cells. A one-time incubation of hematopoietic transplants with MAX.16H5 prolongs survival of NSG (NOD.Cg-PrkdcSCID Il2rgtm1Wjl/SzJ) mice and reduces signs of GVHD manifestation as effectively as repeated application with clinically applied immunosuppressants, making it a safe and effective immunotherapy for GVHD prevention.

Indexed as

Antibodies, MonoclonalCD4 AntigensGraft vs Host DiseaseHematopoietic Stem Cell TransplantationAnimalsCD4-Positive T-LymphocytesHumansMiceMice, Inbred NODAntibodies, MonoclonalCD4 Antigens

Identifiers

PMID41587074
PMCPMC13197980

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.